Total
0
Shares
HeraMED (ASX:HMD) - CEO, David Groberman
CEO, David Groberman
Source: HeraMED
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • HeraMED (HMD) begins a paid pilot of its HeraCARE solution, involving 100 expectant mothers at Western Australia’s Joondalup Health Campus (JHC)
  • The company’s hybrid platform aims to revolutionise the prenatal and postpartum experiences and digitally transform maternity care
  • The pilot will see JHC pay $50 per user per month on a technology-as-a-service recurring revenue model
  • The initiative represents the first phase of an expected commercial rollout that will see the technology offered as a standard service at JHC
  • Shares have closed at 22 cents on August 13

Medical data and tech developer HeraMED (HMD) has begun a paid pilot of its HeraCARE solution, involving 100 expectant mothers at Western Australia’s Joondalup Health Campus (JHC).

HeraMED says it is targeting the digital transformation of maternity care by using its hybrid platform to revolutionise the prenatal and postpartum experiences.

The pilot represents the initial phase of an anticipated commercial rollout that would see the technology used as a standard service offered to all pregnant mothers under JHC’s care.

The pilot initiative will see JHC pay $50 per user per month on a technology-as-a-service recurring revenue model.

Since it was first announced back in April, HMD said its team had been working closely with JHC’s obstetrics department to ensure the platform was fully integrated with the campus’ workflows and clinical pathways before the pilot.

Broadly, Joondalup Health and HMD have been collaborating to incorporate HeraCARE as part of an innovative model for remote monitoring and care management for pregnant women, allowing the use of the HeraBEAT device and foetal heart rate data in JHC’s Telehealth consultations.

Last year the parties undertook a clinical study of HeraMED’s HeraBEAT device, which reportedly showed accuracy greater than the industry standard CTG machine.

HeraMED CEO and Cofounder David Groberman said he was delighted the paid pilot had commenced.

“As part of Australia’s largest private hospital operator, Ramsay Health Care Group, JHC is well regarded as an early adopter of new technologies in obstetrics,” he said.

Joondalup Health Campus CEO Amanda Ling also commented on the partnership.

“We are delighted to be progressing our collaboration with HeraMED and, if this pilot is successful, we would hope to incorporate the platform into our remote monitoring and care management programs for pregnant women,” Dr Ling said.

Joondalup Health Campus is among WA’s latest hospitals and provides maternity care services to an average of 3000 expectant mothers per year.

Shares closed at 22 cents on August 13, 2021.

HMD by the numbers
More From The Market Herald

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.